- Home
- CLB vs CGEM Comparison
CLB vs CGEM Comparison
Compare CLB & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLB
- CGEM
- Stock Information
- Founded
- CLB 1936
- CGEM 2016
- Country
- CLB United States
- CGEM United States
- Employees
- CLB N/A
- CGEM N/A
- Industry
- CLB
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- CLB
- CGEM Health Care
- Exchange
- CLB Nasdaq
- CGEM Nasdaq
- Market Cap
- CLB 553.2M
- CGEM 482.7M
- IPO Year
- CLB 1995
- CGEM 2021
- Fundamental
- Price
- CLB $10.53
- CGEM $7.67
- Analyst Decision
- CLB Hold
- CGEM Strong Buy
- Analyst Count
- CLB 2
- CGEM 6
- Target Price
- CLB $12.50
- CGEM $28.17
- AVG Volume (30 Days)
- CLB 446.2K
- CGEM 298.9K
- Earning Date
- CLB 07-23-2025
- CGEM 08-11-2025
- Dividend Yield
- CLB 0.37%
- CGEM N/A
- EPS Growth
- CLB 23.99
- CGEM N/A
- EPS
- CLB 0.62
- CGEM N/A
- Revenue
- CLB $517,378,000.00
- CGEM N/A
- Revenue This Year
- CLB N/A
- CGEM N/A
- Revenue Next Year
- CLB $2.92
- CGEM N/A
- P/E Ratio
- CLB $17.64
- CGEM N/A
- Revenue Growth
- CLB 0.70
- CGEM N/A
- 52 Week Low
- CLB $10.15
- CGEM $6.85
- 52 Week High
- CLB $24.45
- CGEM $19.89
- Technical
- Relative Strength Index (RSI)
- CLB 38.82
- CGEM 44.23
- Support Level
- CLB $11.72
- CGEM $8.07
- Resistance Level
- CLB $13.79
- CGEM $8.59
- Average True Range (ATR)
- CLB 0.70
- CGEM 0.39
- MACD
- CLB -0.17
- CGEM 0.01
- Stochastic Oscillator
- CLB 7.39
- CGEM 19.53
About CLB Core Laboratories Inc.
Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.